Paper36936142
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.
Zhou P and 5 others. Front Endocrinol (Lausanne), 2023. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Papers, record 36936142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36936142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sodium-Glucose Transporter 2 Inhibitors | Major topic |
| Fatty Liver | Major topic |
| Elasticity Imaging Techniques | Major topic |
| Humans | |
| Liver Cirrhosis |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 2 | 27462372 | Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. | Diabetol Metab Syndr | 2016 | https://conductscience.org/library/papers/27462372 | PubMed |
| 3 | 25524443 | Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. | BMC Med Res Methodol | 2014 | https://conductscience.org/library/papers/25524443 | PubMed |
| 4 | 34602251 | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. | Gastroenterology | 2021 | https://conductscience.org/library/papers/34602251 | PubMed |
| 5 | 34507895 | The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. | Dig Liver Dis | 2022 | https://conductscience.org/library/papers/34507895 | PubMed |
| 6 | 30178600 | Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. | Diabetes Obes Metab | 2019 | https://conductscience.org/library/papers/30178600 | PubMed |
| 7 | 14698338 | Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Ultrasound Med Biol | 2003 | https://conductscience.org/library/papers/14698338 | PubMed |
| 8 | 31963648 | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | J Clin Med | 2020 | https://conductscience.org/library/papers/31963648 | PubMed |
| 9 | 20870345 | Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. | Ultrasound Med Biol | 2010 | https://conductscience.org/library/papers/20870345 | PubMed |
| 10 | 36910362 | Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. | Afr Health Sci | 2022 | https://conductscience.org/library/papers/36910362 | PubMed |
| 11 | 29286050 | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. | Nat Rev Endocrinol | 2018 | https://conductscience.org/library/papers/29286050 | PubMed |
| 12 | 11003611 | Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. | Hepatology | 2000 | https://conductscience.org/library/papers/11003611 | PubMed |
| 13 | 30780126 | Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. | Pharmacol Rep | 2019 | https://conductscience.org/library/papers/30780126 | PubMed |
| 14 | 34858740 | Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. | Cureus | 2021 | https://conductscience.org/library/papers/34858740 | PubMed |
| 15 | 35980569 | Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. | Endocrine | 2022 | https://conductscience.org/library/papers/35980569 | PubMed |
| 16 | 35483674 | Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. | Diabetes Metab J | 2022 | https://conductscience.org/library/papers/35483674 | PubMed |
| 17 | 35089884 | Non-invasive tests of non-alcoholic fatty liver disease. | Chin Med J (Engl) | 2022 | https://conductscience.org/library/papers/35089884 | PubMed |
| 18 | 27683581 | Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. | Stat Methods Med Res | 2018 | https://conductscience.org/library/papers/27683581 | PubMed |
| 19 | 26707365 | Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Hepatology | 2016 | https://conductscience.org/library/papers/26707365 | PubMed |
| 20 | 27183219 | Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. | Hepatol Res | 2016 | https://conductscience.org/library/papers/27183219 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967591 | Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/42967591 | PubMed |
| 42517896 | Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes. | Acta Diabetol | 2026 | https://conductscience.org/library/papers/42517896 | PubMed |
| 42345092 | SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis. | Arterioscler Thromb Vasc Biol | 2026 | https://conductscience.org/library/papers/42345092 | PubMed |
| 41958639 | Natriuretic Effect of Dapagliflozin in Cirrhosis With Ascites: A Randomized, Placebo-Controlled Crossover Trial. | Int J Hepatol | 2026 | https://conductscience.org/library/papers/41958639 | PubMed |
| 41615833 | Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP-ELM study. | J Diabetes Investig | 2026 | https://conductscience.org/library/papers/41615833 | PubMed |
| 41535629 | Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study. | Hepatol Int | 2026 | https://conductscience.org/library/papers/41535629 | PubMed |
| 41497678 | Role of sodium-glucose cotransporter 2 inhibitors in liver diseases. | World J Exp Med | 2025 | https://conductscience.org/library/papers/41497678 | PubMed |
| 41157142 | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use-Reviewing Protective Effects Exceeding Glycemic Control. | Molecules | 2025 | https://conductscience.org/library/papers/41157142 | PubMed |
| 40872510 | SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872510 | PubMed |
| 40630104 | SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40630104 | PubMed |
| 40289065 | Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD. | J Diabetes | 2025 | https://conductscience.org/library/papers/40289065 | PubMed |
| 40075451 | Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis. | BMC Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/40075451 | PubMed |
| 40004772 | SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy. | J Clin Med | 2025 | https://conductscience.org/library/papers/40004772 | PubMed |
| 39812053 | Use of SGLT2 Inhibitors in Frail Older Adults is Associated with Increased Survival: A Retrospective Study. | Curr Pharm Des | 2025 | https://conductscience.org/library/papers/39812053 | PubMed |
| 39699846 | Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet. | Hormones (Athens) | 2025 | https://conductscience.org/library/papers/39699846 | PubMed |
| 39625600 | Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial. | Hepatol Int | 2025 | https://conductscience.org/library/papers/39625600 | PubMed |
| 39599627 | Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. | Nutrients | 2024 | https://conductscience.org/library/papers/39599627 | PubMed |
| 39270669 | Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors. | Am J Epidemiol | 2024 | https://conductscience.org/library/papers/39270669 | PubMed |
| 37634892 | Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/37634892 | PubMed |
| 37109700 | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits? | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/37109700 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36936142
GET https://conductscience.org/api/papers/v1/36936142/references?page=2